Abstract
The use of cytokines in stem cell transplantation is still in the early stages of development. Efficacy has not been established consistently at the present time. When cytokines are employed in the treatment setting, they should be employed in a study setting evaluating whether there has been real patient benefit-palliation without compromise of therapeutic outcome or, preferably, a survival advantage. Cost effectiveness has not been established and, in any case it should not be a consideration until therapeutic efficacy has been established. The determination of various biologic parameters on cells such as cytokine receptors may permit more precise use of HGFs. In some cases there probably are subsets of patients who are benefited, while there are subsets who are harmed. The challenge of the future is to define these subsets.
References
Feb 1, 1992·Annals of Internal Medicine·R AdvaniP L Greenberg
Jan 1, 1992·The American Journal of Pediatric Hematology/oncology·H E Broxmeyer
Feb 1, 1992·Annals of Internal Medicine·S C Gulati, C L Bennett
Feb 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·M MusashiM Ogawa
Jun 20, 1991·The New England Journal of Medicine·J NemunaitisM Gold
Nov 1, 1991·Annals of Hematology·H KöpplerK Havemann
Jun 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M KörblingW Hunstein
Dec 8, 1990·Lancet·R PowlesC Tiley
May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A S FreedmanL Heflin
Oct 14, 1989·Lancet·W P SheridanR M Fox
Apr 7, 1988·The New England Journal of Medicine·S J BrandtD H Oette
Jan 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E J ShpallM Purdy
Mar 19, 1994·Lancet·C GisselbrechtD C Linch
Apr 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G SpitzerW McIntyre
Jun 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J CrownC Hudis
Jul 1, 1994·Stem Cells·C L BennettN C Gorin
Jun 7, 1994·PharmacoEconomics·B R LuceJ Nemunaitis